Skip to main content
Premium Trial:

Request an Annual Quote

Origene Collaborating with PROOF Centre on Protein Diagnostics for Heart and Kidney Transplants

Premium

Canada's Centre of Excellence for the Prevention of Organ Failure – also called the PROOF Centre – has partnered with Origene Technologies on blood-based protein assays for monitoring heart and kidney transplantation.

The agreement covers a multi-year project that aims to provide monitoring and predictive blood tests for heart and kidney transplant patients. Origene will use its experience in monoclonal antibody production and Luminex multiplex assay development to build and implement diagnostic assays for transplant care, the company said in a statement.

It added that this was "the first announced clinical development project" using Origene's UltraMAB antibodies – a recently released line of antibodies that the company said are "validated for specificity and low cross-reactivity."

According to a recent study by the PROOF Centre, implementation of blood-based protein tests for organ rejection could save British Columbia up to C$700,000 (US$700,000) over five years.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.